Ono Pharmaceutical Co., Ltd. (ON4.F)
| Previous close | 12.40 |
| Open | 12.50 |
| Bid | 12.50 x N/A |
| Ask | 13.10 x N/A |
| Day's range | 12.50 - 12.50 |
| 52-week range | 12.20 - 18.20 |
| Volume | |
| Avg. volume | 57 |
| Market cap | 6.049B |
| Beta (5Y monthly) | 0.18 |
| PE ratio (TTM) | 8.12 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.48 (3.88%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- PR Newswire
ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH, Chief Executive Officer: Steven L. Hoerter, "Deciphera") today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer follow
- PR Newswire
Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that in order to accelerate the open innovation, it has increased its investment pool from US$100 million to US$200 million to continue strategic investment in Ono Venture Investment Fund I, L.P. ("OVI FI"), which was established as a corporate venture capital fund in CA, USA in May 2020.
